{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:06:22Z","timestamp":1785553582398,"version":"3.56.0"},"reference-count":206,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.autrev.2017.03.010","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T04:31:51Z","timestamp":1488947511000},"page":"445-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":163,"title":["Bullous pemphigoid"],"prefix":"10.1016","volume":"16","author":[{"given":"I\u015f\u0131n Sinem","family":"Ba\u011fc\u0131","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsolya N.","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ruzicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"S\u00e1rdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2017.03.010_bb0005","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.autrev.2014.01.047","article-title":"Diagnosis and classification of autoimmune blistering diseases","volume":"13","author":"Baum","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.03.010_bb0010","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.clim.2008.04.012","article-title":"Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid","volume":"12","author":"Di Zenzo","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0015","doi-asserted-by":"publisher","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2013incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2017.03.010_bb0020","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0025","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2133.2005.06662.x","article-title":"Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland","volume":"153","author":"Gudi","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0030","first-page":"434","article-title":"Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany","volume":"7","author":"Bertram","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.autrev.2017.03.010_bb0035","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1365-2133.2009.09300.x","article-title":"Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study","volume":"161","author":"Marazza","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0040","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1365-4632.2009.04345.x","article-title":"Pemphigus vulgaris is the most common autoimmune bullous disease in northwestern Romania","volume":"49","author":"Baican","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0045","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0190-9622(99)70061-7","article-title":"Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence","volume":"41","author":"Jung","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0050","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions","volume":"131","author":"Bernard","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0055","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2014.02.030","article-title":"Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009","volume":"71","author":"Brick","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0060","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jaad.2007.08.010","article-title":"Bullous pemphigoid in infancy: clinical and epidemiologic characteristics","volume":"58","author":"Waisbourd-Zinman","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0065","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clindermatol.2011.03.005","article-title":"Bullous pemphigoid: from the clinic to the bench","volume":"30","author":"Di Zenzo","year":"2012","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0070","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jaad.2014.05.006","article-title":"Mortality of patients with bullous pemphigoid in Korea","volume":"71","author":"Lee","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0075","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.03.010_bb0080","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/archderm.138.7.903","article-title":"Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age","volume":"138","author":"Rzany","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0085","first-page":"141","article-title":"Autoimmunity in chronic bullous skin diseases. Immunofluorescent demonstration of three types of antibodies to skin in sera of patients with pemphigus, bullous pemphigoid and in other human sera","volume":"2","author":"Beutner","year":"1967","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0090","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1001\/jama.1967.03120220053008","article-title":"Basement zone antibodies in bullous pemphigoid","volume":"200","author":"Jordon","year":"1967","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2017.03.010_bb0095","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00441-015-2216-6","article-title":"Molecular architecture and function of the hemidesmosome","volume":"360","author":"Walko","year":"2015","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.autrev.2017.03.010_bb0100","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1172\/JCI116856","article-title":"A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180","volume":"92","author":"Liu","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2017.03.010_bb0105","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1172\/JCI117826","article-title":"The role of complement in experimental bullous pemphigoid","volume":"95","author":"Liu","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2017.03.010_bb0110","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1172\/JCI119639","article-title":"A major role for neutrophils in experimental bullous pemphigoid","volume":"100","author":"Liu","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2017.03.010_bb0115","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1172\/JCI11494","article-title":"Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid","volume":"108","author":"Chen","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2017.03.010_bb0120","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nm1496","article-title":"Humanization of autoantigen","volume":"13","author":"Nishie","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2017.03.010_bb0125","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jaut.2008.08.009","article-title":"Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model","volume":"31","author":"Liu","year":"2008","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2017.03.010_bb0130","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.4049\/jimmunol.0903101","article-title":"A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen","volume":"184","author":"Ujiie","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0135","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1046\/j.1523-1747.2002.01720.x","article-title":"Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin","volume":"118","author":"Sitaru","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0140","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.4049\/jimmunol.176.3.2015","article-title":"Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230","volume":"176","author":"Thoma-Uszynski","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0145","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1172\/JCI28547","article-title":"T cell control in autoimmune bullous skin disorders","volume":"116","author":"Hertl","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2017.03.010_bb0150","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.4049\/jimmunol.169.7.3987","article-title":"Macrophages, but not T and B lymphocytes, are critical for subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated neutrophil infiltration depends on mast cell activation","volume":"169","author":"Chen","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0155","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/j.1365-2133.2004.06245.x","article-title":"Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients","volume":"151","author":"Mariotti","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0160","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2012.09.012","article-title":"Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbant assay","volume":"68","author":"Fairley","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0165","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/archderm.136.2.174","article-title":"Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid","volume":"136","author":"Schmidt","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0170","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jdermsci.2004.10.007","article-title":"Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid","volume":"37","author":"Tsuji-Abe","year":"2005","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.autrev.2017.03.010_bb0175","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1046\/j.1523-1747.2002.19529.x","article-title":"Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain","volume":"119","author":"Hofmann","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0180","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jaut.2016.06.019","article-title":"IgG4 autoantibodies are inhibitory in the autoimmune disease bullous pemphigoid","volume":"73","author":"Zuo","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2017.03.010_bb0185","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jim.2009.04.013","article-title":"A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid","volume":"346","author":"Messingham","year":"2009","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.autrev.2017.03.010_bb0190","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/sj.jid.5700681","article-title":"IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice","volume":"127","author":"Zone","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0195","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1038\/sj.jid.5700958","article-title":"A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu\/nu mice","volume":"127","author":"Fairley","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0200","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1046\/j.1523-1747.2003.12146.x","article-title":"Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid","volume":"120","author":"Dimson","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0205","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.4049\/jimmunol.157.8.3642","article-title":"IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid","volume":"157","author":"Delaporte","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0210","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jdermsci.2005.11.002","article-title":"Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid","volume":"41","author":"Yoshida","year":"2006","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.autrev.2017.03.010_bb0215","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/08916934.2011.606447","article-title":"Pemphigoid diseases: pathogenesis, diagnosis, and treatment","volume":"45","author":"Kasperkiewicz","year":"2012","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2017.03.010_bb0220","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/j.0022-202X.2004.22603.x","article-title":"BP230- and BP180-specific auto-antibodies in bullous pemphigoid","volume":"122","author":"Thoma-Uszynski","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0225","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/bjd.14542","article-title":"Subepidermal autoimmune bullous disease affecting predominantly mucocutaneous junctions and the palms with autoantibodies to BP230 and laminin \u03b31","volume":"175","author":"Honda","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0230","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bjd.12936","article-title":"BP180- and BP230-specific IgG autoantibodies in pruritic disorders of the elderly: a preclinical stage of bullous pemphigoid?","volume":"171","author":"Schmidt","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0235","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.clindermatol.2013.01.006","article-title":"Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies","volume":"31","author":"Lo Schiavo","year":"2013","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0240","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12016-007-0030-y","article-title":"The pathophysiology of bullous pemphigoid","volume":"33","author":"Kasperkiewicz","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0245","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1172\/JCI117196","article-title":"92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180kD in bullous pemphigoid autoantigen","volume":"93","author":"Stahle-B\u00e4ckdahl","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2017.03.010_bb0250","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1046\/j.0022-202x.2001.01521.x","article-title":"Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid","volume":"117","author":"Verraes","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0255","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1046\/j.1523-1747.2000.00141.x","article-title":"Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes","volume":"115","author":"Schmidt","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0260","doi-asserted-by":"publisher","first-page":"37358","DOI":"10.1074\/jbc.M111.272401","article-title":"Dual targets for mouse mast cell protease-4 in mediating tissue damage in experimental bullous pemphigoid","volume":"286","author":"Lin","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2017.03.010_bb0265","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/jid.2014.263","article-title":"Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid","volume":"134","author":"Le Jan","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0270","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/srep18001","article-title":"Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome","volume":"5","author":"Pl\u00e9e","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2017.03.010_bb0275","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.4049\/jimmunol.1400095","article-title":"Bullous pemphigoid autoantibodies directly induce blister formation without complement activation","volume":"193","author":"Ujiie","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0280","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/jid.2008.305","article-title":"IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment","volume":"129","author":"Iwata","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0285","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-007-0734-0","article-title":"The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases","volume":"299","author":"Sitaru","year":"2007","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.autrev.2017.03.010_bb0290","first-page":"57","article-title":"Effector mechanisms activated by human IgG subclass antibodies: clinical and molecular aspects","volume":"52","author":"Jefferis","year":"1994","journal-title":"Ann Biol Clin"},{"key":"10.1016\/j.autrev.2017.03.010_bb0295","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjd.14411","article-title":"Bullous pemphigoid suggestive of complement-independent blister formation with anti-BP180 IgG4 autoantibodies","volume":"175","author":"Dainichi","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0300","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.4049\/jimmunol.1003402","article-title":"Antibodies to pathogenic epitopes on type XVII collagen cause skin fragility in a complement-dependent and -independent manner","volume":"188","author":"Natsuga","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0305","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1046\/j.0022-202x.2001.01505.x","article-title":"Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells","volume":"117","author":"Teraki","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0310","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1046\/j.1365-2133.1998.02169.x","article-title":"Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity","volume":"138","author":"Ameglio","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0315","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1046\/j.1365-2133.2000.03894.x","article-title":"High levels of interleukin-8, soluble CD4 and soluble CD8 in bullous pemphigoid blister fluid. The relationship between local cytokine production and lesional T-cell activities","volume":"143","author":"Sun","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0320","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1046\/j.1365-2133.1999.02907.x","article-title":"Characterization of skin cytokines in bullous pemphigoid and pemphigus vulgaris","volume":"140","author":"Rico","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0325","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/000155599750010689","article-title":"Blister fluid cytokines in cutaneous inflammatory bullous disorders","volume":"79","author":"Rhodes","year":"1999","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0330","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/srep18001","article-title":"Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome","volume":"5","author":"Pl\u00e9e","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2017.03.010_bb0335","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/jid.2014.263","article-title":"Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid","volume":"134","author":"Le Jan","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0340","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.clim.2006.03.014","article-title":"Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines","volume":"120","author":"Gounni Abdelilah","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0345","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/j.1365-2133.2008.08979.x","article-title":"CCL18 is expressed in patients with bullous pemphigoid and parallels disease course","volume":"160","author":"G\u00fcnther","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0350","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/jid.2011.251","article-title":"High levels of CCL26 in blister fluid and sera of patients with bullous pemphigoid","volume":"132","author":"Kagami","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0355","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/j.0022-202X.2005.23700.x","article-title":"Increased serum CCL28 levels in patients with atopic dermatitis, psoriasis vulgaris and bullous pemphigoid","volume":"124","author":"Kagami","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0360","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jdermsci.2008.10.012","article-title":"Increased CCL1 levels in the sera and blister fluid of patients with bullous pemphigoid","volume":"54","author":"Miyagaki","year":"2009","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.autrev.2017.03.010_bb0365","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1365-2133.2006.07601.x","article-title":"Serum chemokine profile in patients with bullous pemphigoid","volume":"156","author":"Nakashima","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0370","doi-asserted-by":"publisher","first-page":"8569","DOI":"10.1073\/pnas.93.16.8569","article-title":"A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid","volume":"93","author":"Delgado","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2017.03.010_bb0375","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2249.2010.04239.x","article-title":"Relationship between target antigens and major histocompatibility complex (MHC) class II genes in producing two pathogenic antibodies simultaneously","volume":"162","author":"Zakka","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0380","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/1523-1747.ep12332352","article-title":"Significantly increased occurrence of HLA-DQB1*0301 allele in patients with ocular cicatricial pemphigoid","volume":"108","author":"Chan","year":"1997","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0385","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1046\/j.1365-2133.2001.04380.x","article-title":"Mucous membrane pemphigoid:HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production","volume":"145","author":"Setterfield","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0390","first-page":"330","article-title":"HLA-DRB1 and HLA-DQB1 genes in susceptibility and resistance to cicatricial pemphigoid in French Caucasians","volume":"8","author":"Drouet","year":"1998","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0395","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1172\/JCI3335","article-title":"Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls","volume":"102","author":"B\u00fcdinger","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2017.03.010_bb0400","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nri2454","article-title":"The who, how and where of antigen presentation to B cells","volume":"9","author":"Batista","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0405","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1346-8138.2000.tb02141.x","article-title":"Polymorphisms of HLA-DR and -DQ genes in Japanese patients with bullous pemphigoid","volume":"27","author":"Okazaki","year":"2000","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0410","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/exd.12732","article-title":"Polymorphisms in the mitochondrially encoded ATP synthase 8 gene are associated with susceptibility to bullous pemphigoid in the German population","volume":"24","author":"Hirose","year":"2015","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0415","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/exd.12772","article-title":"The mitochondrion is a common target of disease pathophysiology in pemphigus and pemphigoid","volume":"24","author":"Grando","year":"2015","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0420","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/ijd.12967","article-title":"The impact of the CYP2D6 gene polymorphism on the risk of pemphigoid","volume":"54","author":"Rychlik-Sych","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0425","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00403-007-0755-8","article-title":"Relevance of the low-affinity type of the Fcgamma-receptor IIIa-polymorphism in bullous pemphigoid","volume":"299","author":"Weisenseel","year":"2007","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.autrev.2017.03.010_bb0430","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1365-2133.1995.tb00739.x","article-title":"Induced bullous pemphigoid","volume":"132","author":"Venning","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0435","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0738-081X(98)00008-X","article-title":"Drug-induced pemphigoid: bullous and cicatricial","volume":"16","author":"Vassileva","year":"1998","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0440","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-4362.1991.tb03867.x","article-title":"Pemphigus and bullous pemphigoid due to drugs","volume":"30","author":"Ruocco","year":"1991","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0445","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French pharmacovigilance database","volume":"175","author":"B\u00e9n\u00e9","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0450","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3315\/jdcr.2011.1081","article-title":"Bullous pemphigoid triggered by swine flu vaccination: case report and review of vaccine triggered pemphigoid","volume":"5","author":"Walmsley","year":"2011","journal-title":"J Dermatol Case Rep"},{"key":"10.1016\/j.autrev.2017.03.010_bb0455","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0001-7310(05)73081-7","article-title":"Bullous pemphigoid in an infant after vaccination","volume":"96","author":"M\u00e9rida","year":"2005","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.autrev.2017.03.010_bb0460","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1067\/mjd.2001.103034","article-title":"Childhood bullous pemphigoid developed after the first vaccination","volume":"44","author":"Baykal","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0465","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1365-2133.2006.07411.x","article-title":"Bullous pemphigoid triggered by influenza vaccination? Ecological study in Galicia, Spain","volume":"155","author":"Garc\u00eda-Doval","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0470","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/pde.12231","article-title":"Postvaccination bullous pemphigoid in infancy: report of three new cases and literature review","volume":"30","author":"de la Fuente","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0475","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/jjco\/hyr049","article-title":"A case of bullous pemphigoid exacerbated by irradiation after breast conservative radiotherapy","volume":"41","author":"Isohashi","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0480","first-page":"70","article-title":"Localized bullous pemphigoid following radiotherapy","volume":"127","author":"Leconte-Boulard","year":"2000","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0485","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/j.1365-2230.2012.04402.x","article-title":"Bullous pemphigoid induced by radiotherapy recurring on rechallenge","volume":"37","author":"Sears","year":"2012","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0490","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/jjco\/hyr049","article-title":"A case of bullous pemphigoid exacerbated by irradiation after breast conservative radiotherapy","volume":"41","author":"Isohashi","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0495","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1524-4741.2010.01060.x","article-title":"Bullous pemphigoid following adjuvant radiotherapy for breast cancer","volume":"17","author":"Olsha","year":"2011","journal-title":"Breast J"},{"key":"10.1016\/j.autrev.2017.03.010_bb0500","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4103\/2229-5178.146170","article-title":"Localized bullous pemphigoid on sites of radiotherapy and lymphedema in the same patient","volume":"5","author":"Binitha","year":"2014","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.autrev.2017.03.010_bb0505","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/00015550510035677","article-title":"Bullous pemphigoid in psoriasis lesions after UVA radiation","volume":"85","author":"Washio","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0510","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2340\/0001555576330331","article-title":"Localised bullous pemphigoid following radiotherapy","volume":"76","author":"Cliff","year":"1996","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0515","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1365-4362.1994.tb01498.x","article-title":"Bullous pemphigoid induced by a thermal burn","volume":"33","author":"Balato","year":"1994","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0520","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/SMJ.0b013e3181efb58c","article-title":"Bullous pemphigoid after boiling water burn","volume":"103","author":"Bachmeyer","year":"2010","journal-title":"South Med J"},{"key":"10.1016\/j.autrev.2017.03.010_bb0525","first-page":"169","article-title":"Flare of bullous pemphigoid in surgically treated skin","volume":"75","author":"Neville","year":"2005","journal-title":"Cutis"},{"key":"10.1016\/j.autrev.2017.03.010_bb0530","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1046\/j.1523-1747.1998.00107.x","article-title":"Epitope spreading: lessons from autoimmune skin diseases","volume":"110","author":"Chan","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0535","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000106574","article-title":"Neurological disorders in patients with bullous pemphigoid","volume":"215","author":"Cordel","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2017.03.010_bb0540","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.jaad.2014.07.052","article-title":"A population-based study of the association between bullous pemphigoid and neurologic disorders","volume":"71","author":"Brick","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0545","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: a prospective case-control study","volume":"131","author":"Bastuji-Garin","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0550","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1684\/ejd.2010.0805","article-title":"Bullous pemphigoid and internal diseases: a case-control study","volume":"20","author":"Jedlickova","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0555","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.matbio.2005.11.004","article-title":"Collagen XVII is expressed in human CNS neurons","volume":"25","author":"Sepp\u00e4nen","year":"2006","journal-title":"Matrix Biol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0560","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000315393","article-title":"Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain","volume":"57","author":"Chen","year":"2011","journal-title":"Gerontology"},{"key":"10.1016\/j.autrev.2017.03.010_bb0565","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/exd.12877","article-title":"One gene but different proteins and diseases: the complexity of dystonin and bullous pemphigoid antigen 1","volume":"25","author":"K\u00fcnzli","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0570","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.humimm.2014.01.005","article-title":"IgG antibodies against immunodominant C-terminal epitopes of BP230 do not induce skin blistering in mice","volume":"75","author":"Feldrihan","year":"2014","journal-title":"Hum Immunol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0575","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1365-2133.2011.10386.x","article-title":"Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study","volume":"165","author":"Chen","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0580","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4103\/0022-3859.150906","article-title":"A case of paraneoplastic bullous pemphigoid in association with squamous cell carcinoma of lung","volume":"61","author":"Das","year":"2015","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.autrev.2017.03.010_bb0585","first-page":"2128","article-title":"A case of bullous pemphigoid relieved after sigmoid colon cancer resection","volume":"42","author":"Kimura","year":"2015","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.autrev.2017.03.010_bb0590","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pneumo.2013.11.011","article-title":"Small cell lung cancer associated with paraneoplastic bullous pemphigoid","volume":"70","author":"Lakhdar","year":"2014","journal-title":"Rev Pneumol Clin"},{"key":"10.1016\/j.autrev.2017.03.010_bb0595","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijscr.2014.02.008","article-title":"Dramatic resolution of bullous pemphigoid after surgery for gastric cancer: a case report","volume":"5","author":"Noguchi","year":"2014","journal-title":"Int J Surg Case Rep"},{"key":"10.1016\/j.autrev.2017.03.010_bb0600","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.clindermatol.2013.01.007","article-title":"Bullous pemphigoid: associations and management guidelines: facts and controversies","volume":"31","author":"Ruocco","year":"2013","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0605","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.yadr.2007.07.013","article-title":"Bullous pemphigoid: physiopathology, clinical features and management","volume":"23","author":"Di Zenzo","year":"2007","journal-title":"Adv Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0610","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-4632.2004.02457.x","article-title":"Prodromal bullous pemphigoid","volume":"45","author":"Lamb","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0615","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.autrev.2015.01.006","article-title":"Atypical presentations of bullous pemphigoid: clinical and immunopathological aspects","volume":"14","author":"Cozzani","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.03.010_bb0620","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2165\/00003495-200565070-00002","article-title":"Bullous pemphigoid: from bench to bedside","volume":"65","author":"Walsh","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2017.03.010_bb0625","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.clim.2008.04.012","article-title":"Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid","volume":"128","author":"Di Zenzo","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0630","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1001\/jamadermatol.2014.54","article-title":"Toward a practical renaming of bullous pemphigoid and all its variants-reply","volume":"150","author":"Bakker","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0635","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/jamadermatol.2013.756","article-title":"Bullous pemphigoid as pruritus in the elderly: a common presentation","volume":"149","author":"Bakker","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0640","first-page":"225","article-title":"Bullous pemphigoid: persistent lesions of eczematous\/urticarial erythemas","volume":"56","author":"Jeong","year":"1995","journal-title":"Cutis"},{"key":"10.1016\/j.autrev.2017.03.010_bb0645","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1365-4362.1992.tb03546.x","article-title":"Vesicular pemphigoid","volume":"31","author":"Komine","year":"1992","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0650","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1365-2230.2008.03083.x","article-title":"Two cases of dyshidrosiform pemphigoid with different presentations","volume":"34","author":"Yasuda","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0655","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jaad.2009.06.078","article-title":"A case of pemphigoid vegetans with autoantibodies against both BP180 and BP230 antigens","volume":"64","author":"Suda-Takayanagi","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0660","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S0190-9622(98)70358-5","article-title":"Bullous pemphigoid presenting as exfoliative erythroderma","volume":"39","author":"Alonso-Llamazares","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0665","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/pde.12214","article-title":"Childhood lichen planus pemphigoides: report of two cases treated successfully with systemic glucocorticoids and dapsone","volume":"31","author":"Goldscheider","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0670","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1046\/j.1365-2230.1999.00528.x","article-title":"Figurate erythema with bullous pemphigoid: a true paraneoplastic phenomenon?","volume":"24","author":"Gilmour","year":"1999","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0675","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000322842","article-title":"Brunsting-Perry pemphigoid of the scalp with antibodies against laminin 332","volume":"222","author":"Jedlickova","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2017.03.010_bb0680","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1468-3083.2008.02702.x","article-title":"Localized pemphigoid (Brunsting-Perry type) with IgG antibody to BP180 NC16a domain resembling lupus erythematosus successfully treated with topical tacrolimus therapy","volume":"23","author":"Demitsu","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0685","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0190-9622(93)70016-M","article-title":"Brunsting-Perry cicatricial bullous pemphigoid: a clinical variant of localized acquired epidermolysis bullosa?","volume":"28","author":"Joly","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0690","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1365-2133.2011.10343.x","article-title":"Brunsting-Perry type pemphigoid with IgG autoantibodies to laminin-332, BP230 and desmoplakins I\/II","volume":"165","author":"Fukuda","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0695","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.autrev.2015.01.006","article-title":"Atypical presentations of bullous pemphigoid: clinical and immunopathological aspects","volume":"14","author":"Cozzani","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.03.010_bb0700","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1046\/j.1365-2133.1999.02668.x","article-title":"Childhood vulval pemphigoid: a clinical and immunopathological study of five patients","volume":"140","author":"Farrell","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0705","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2340\/00015555-0644","article-title":"Bullous pemphigoid with localized umbilical involvement","volume":"89","author":"Schmidt","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0710","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-4362.1983.tb03375.x","article-title":"Hydrostatic bullae and pretibial pemphigoid","volume":"22","author":"Person","year":"1983","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0715","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/0190-9622(92)70268-K","article-title":"Localized pretibial pemphigoid and pemphigoid nodularis","volume":"27","author":"Borradori","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0720","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1365-2133.1992.tb00110.x","article-title":"Unilateral bullous pemphigoid in a hemiplegic patient","volume":"126","author":"Long","year":"1992","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0725","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"The European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0730","first-page":"833","article-title":"S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid","volume":"13","author":"Eming","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.autrev.2017.03.010_bb0735","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1085-5629(96)80044-7","article-title":"Eosinophilic and neutrophilic spongiosis: clues to the diagnosis of immunobullous diseases and other inflammatory disorders","volume":"15","author":"Machado-Pinto","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.autrev.2017.03.010_bb0740","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jaad.2013.07.009","article-title":"Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid","volume":"69","author":"S\u00e1rdy","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0745","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1365-2133.2004.06006.x","article-title":"U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases","volume":"151","author":"Vodegel","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0750","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-2615","article-title":"Diagnostic value of linear fluorescence along the basement membrane of sweat gland ducts in bullous pemphigoid","author":"Ba\u011fc\u0131","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0755","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2017.03.010_bb0760","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1001\/archdermatol.2009.53","article-title":"Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study","volume":"145","author":"Bernard","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0765","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/15665240113136660079","article-title":"Molecular diagnosis in autoimmune skin blistering conditions","volume":"14","author":"Otten","year":"2014","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.autrev.2017.03.010_bb0770","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1046\/j.1365-2133.2003.05603.x","article-title":"Diagnostic value of an enzyme-linked immunosorbent assay using BP180 recombinant proteins in elderly patients with pruritic skin disorders","volume":"149","author":"Hofmann","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0775","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/archdermatol.2009.331","article-title":"Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects","volume":"146","author":"Wieland","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0780","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/j.1365-2133.2011.10481.x","article-title":"Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis","volume":"165","author":"Yayli","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0785","first-page":"833","article-title":"S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid","volume":"13","author":"Eming","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.autrev.2017.03.010_bb0795","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/bjd.12072","article-title":"British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012","volume":"167","author":"Venning","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0800","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00105-015-3649-2","article-title":"Pemphigoid diseases. Autoimmune diseases in the elderly","volume":"66","author":"Horv\u00e1th","year":"2015","journal-title":"Hautarzt"},{"key":"10.1016\/j.autrev.2017.03.010_bb0805","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/jid.2008.412","article-title":"A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study","volume":"129","author":"Joly","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0810","first-page":"10","article-title":"Interventions for bullous pemphigoid","volume":"6","author":"Kirtschig","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2017.03.010_bb0815","first-page":"927","article-title":"Autoimmune bullous skin diseases. Part 2: diagnosis and therapy","volume":"9","author":"Kneisel","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.autrev.2017.03.010_bb0820","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/jdv.12153","article-title":"Whole body application of a potent topical corticosteroid for bullous pemphigoid","volume":"28","author":"Terra","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0825","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","article-title":"Adverse effects of topical glucocorticosteroids","volume":"54","author":"Hengge","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0830","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1365-2133.2011.10413.x","article-title":"Mortality of bullous pemphigoid in Switzerland: a prospective study","volume":"165","author":"Cortes","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0835","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/archderm.141.6.691","article-title":"Prediction of survival for patients with bullous pemphigoid: a prospective study","volume":"141","author":"Joly","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0840","first-page":"925","article-title":"Treatment of bullous pemphigoid with prednisolone only: 0.75mg\/kg\/day versus 1.25mg\/kg\/day. A multicenter randomized study","volume":"111","author":"Morel","year":"1984","journal-title":"Ann Dermatol V\u00e9n\u00e9r\u00e9ol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0845","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/ced.12042","article-title":"The approach of dermatologists in the UK to the treatment of bullous pemphigoid: results of a national survey","volume":"38","author":"Taghipour","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0850","first-page":"227","article-title":"Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid","volume":"7","author":"Hofmann","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.autrev.2017.03.010_bb0855","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1016\/j.jaad.2010.09.718","article-title":"Nonbullous pemphigoid treated with doxycycline monotherapy: report of 4 cases","volume":"64","author":"Safa","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0860","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bjd.13729","volume":"173","author":"Chalmers","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0865","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/bjd.13844","article-title":"Doxycycline in the treatment of bullous pemphigoid: as good as systemic corticosteroids?","volume":"173","author":"Hofmann","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0870","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/archderm.143.12.1536","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid","volume":"143","author":"Beissert","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0875","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S0190-9622(94)70227-6","article-title":"Low-dose methotrexate treatment in elderly patients with bullous pemphigoid","volume":"31","author":"Paul","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0880","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/archderm.138.9.1255","article-title":"Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: an open prospective study of 18 cases","volume":"138","author":"Dereure","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0885","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/j.1365-2133.2011.10531.x","article-title":"Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study","volume":"165","author":"Du-Thanh","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0890","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamadermatol.2013.5757","article-title":"Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study","volume":"150","author":"Fichel","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0895","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2340\/00015555-1925","article-title":"A retrospective consecutive case-series study on the effect of systemic treatment, length of admission time, and co-morbidities in 98 bullous pemphigoid patients admitted to a tertiary centre","volume":"95","author":"Kibsgaard","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0900","first-page":"205","article-title":"Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases","volume":"76","author":"Schmidt","year":"2005","journal-title":"Cutis"},{"key":"10.1016\/j.autrev.2017.03.010_bb0905","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1365-2133.1989.tb07769.x","article-title":"Dapsone as first line therapy for bullous pemphigoid","volume":"120","author":"Venning","year":"1989","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0910","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/jdv.13758","article-title":"Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature","volume":"30","author":"Balakirski","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0915","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1001\/archdermatol.2012.1604","article-title":"Successful treatment of bullous pemphigoid with omalizumab","volume":"148","author":"London","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0920","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/j.1365-2133.2011.10748.x","article-title":"Successful management of severe infant bullous pemphigoid with omalizumab","volume":"166","author":"Dufour","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0925","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2008.11.035","article-title":"Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab","volume":"123","author":"Fairley","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0930","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0935","doi-asserted-by":"publisher","first-page":"523","DOI":"10.7754\/Clin.Lab.2013.130642","article-title":"Anti-IgE monoclonal antibody(omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200","volume":"60","author":"Yalcin","year":"2014","journal-title":"Clin Lab"},{"key":"10.1016\/j.autrev.2017.03.010_bb0940","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1744-9987.2012.01075.x","article-title":"Immunoadsorption in dermatology","volume":"16","author":"Meyersburg","year":"2012","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.autrev.2017.03.010_bb0945","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.jaad.2014.06.014","article-title":"Treatment of bullous pemphigoid with adjuvant immunoadsorption: a case series","volume":"71","author":"Kasperkiewicz","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0950","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00403-015-1606-7","article-title":"Immunoadsorber for specific apheresis of autoantibodies in the treatment of bullous pemphigoid","volume":"308","author":"Mersmann","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.autrev.2017.03.010_bb0955","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jaad.2015.11.030","article-title":"Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: a retrospective study with a 6-year follow-up","volume":"74","author":"Ahmed","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0960","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2340\/00015555-1619","article-title":"Remission of bullous pemphigoid after rituximab treatment in a psoriasis patient on regular low-dose methotrexate","volume":"94","author":"Wang","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0965","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients","volume":"65","author":"Kasperkiewicz","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0970","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/sj.bmt.1703654","article-title":"Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease","volume":"30","author":"Szabolcs","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2017.03.010_bb0975","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/annonc\/mdn046","article-title":"A new approach on bullous pemphigoid therapy","volume":"19","author":"Saouli","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0980","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","article-title":"Rituximab in autoimmune bullous diseases: mixed responses and adverse effects","volume":"156","author":"Schmidt","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0985","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1525-1470.2008.00751.x","article-title":"Severe bullous pemphigoid in an infant--successful treatment with rituximab","volume":"25","author":"Schulze","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0990","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1365-2133.2007.07982.x","article-title":"Severe persistent pemphigoid gestationis: long-term remission with rituximab","volume":"157","author":"Cianchini","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb0995","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1365-2230.2006.02151.x","article-title":"Rituximab in refractory autoimmune bullous diseases","volume":"31","author":"Schmidt","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb1000","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab(anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.autrev.2017.03.010_bb1005","first-page":"111","article-title":"B-cell targeted therapy alone may not be effective in bullous pemphigoid","volume":"32","author":"Chee","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb1010","first-page":"672","article-title":"Treatment of bullous pemphigoid with rituximab: critical analysis of the current literature","volume":"12","author":"Shetty","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb1015","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/bjd.13633","article-title":"First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid","volume":"173","author":"Cho","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.03.010_bb1020","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1111\/jdv.13725","article-title":"European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology","volume":"30","author":"Enk","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2017.03.010_bb1025","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10354-014-0294-9","article-title":"Bull\u00f6ses Pemphigoid \u2013 Diagnostik und Therapie","volume":"164","author":"Kneisel","year":"2014","journal-title":"Wien Med Wochenschr"},{"key":"10.1016\/j.autrev.2017.03.010_bb1030","first-page":"727","article-title":"Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases","volume":"10","author":"Kasperkiewicz","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.autrev.2017.03.010_bb1035","first-page":"672","article-title":"Treatment of bullous pemphigoid with rituximab: critical analysis of the current literature","volume":"12","author":"Shetty","year":"2013","journal-title":"J Drugs Dermatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217300630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217300630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T14:39:57Z","timestamp":1692715197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997217300630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":206,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1568997217300630"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2017.03.010","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bullous pemphigoid","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2017.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}